Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Chemerinski, Eran
Siever, Larry J.
and
Koenigsberg, Harold W.
2005.
Dopamine regulation in schizotypal personality disorder and psychosis.
Current Psychosis & Therapeutics Reports,
Vol. 3,
Issue. 4,
p.
162.
Joyce, Jeffrey N.
and
Millan, Mark J.
2005.
Dopamine D3 receptor antagonists as therapeutic agents.
Drug Discovery Today,
Vol. 10,
Issue. 13,
p.
917.
Millan, Mark J.
2005.
Le récepteur dopaminergique D3: nouvelle cible pour un traitement amélioré de la schizophrénie.
médecine/sciences,
Vol. 21,
Issue. 4,
p.
434.
Rogers, Bruce N.
and
Schmidt, Christopher J.
2006.
Annual Reports in Medicinal Chemistry Volume 41.
Vol. 41,
Issue. ,
p.
3.
Millan, M.J.
Panayi, F.
Rivet, J.M.
Cara, B. Di
Cistarelli, L.
Billiras, R.
Girardon, S.
and
Gobert, A.
2006.
Handbook of Microdialysis - Methods, Applications and Perspectives.
Vol. 16,
Issue. ,
p.
485.
Lindsey, Kimberly P.
and
Gatley, S. John
2006.
Applications of Clinical Dopamine Imaging.
Neuroimaging Clinics of North America,
Vol. 16,
Issue. 4,
p.
553.
Assié, Marie-Bernadette
Dominguez, Hélène
Consul-Denjean, Nathalie
and
Newman-Tancredi, Adrian
2006.
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Naunyn-Schmiedeberg's Archives of Pharmacology,
Vol. 373,
Issue. 6,
p.
441.
Lindsey, Kimberly P.
and
Gatley, S. John
2007.
Applications of Clinical Dopamine Imaging.
PET Clinics,
Vol. 2,
Issue. 1,
p.
45.
Lambe, E.K.
and
Aghajanian, G.K.
2007.
Prefrontal cortical network activity: Opposite effects of psychedelic hallucinogens and D1/D5 dopamine receptor activation.
Neuroscience,
Vol. 145,
Issue. 3,
p.
900.
Hammoud, Dima A.
Hoffman, John M.
and
Pomper, Martin G.
2007.
Molecular Neuroimaging: From Conventional to Emerging Techniques.
Radiology,
Vol. 245,
Issue. 1,
p.
21.
Zipursky, Robert B
Meyer, Jeffrey H
and
Verhoeff, N Paul
2007.
PET and SPECT Imaging in Psychiatric Disorders.
The Canadian Journal of Psychiatry,
Vol. 52,
Issue. 3,
p.
146.
Guillin, Olivier
Abi‐Dargham, Anissa
and
Laruelle, Marc
2007.
Integrating the Neurobiology of Schizophrenia.
Vol. 78,
Issue. ,
p.
1.
Mu, Qiwen
Johnson, Kevin
Morgan, Paul S.
Grenesko, Emily L.
Molnar, Christine E.
Anderson, Berry
Nahas, Ziad
Kozel, F. Andrew
Kose, Samet
Knable, Michael
Fernandes, Prabhavathi
Nichols, David E.
Mailman, Richard B.
and
George, Mark S.
2007.
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.
Schizophrenia Research,
Vol. 94,
Issue. 1-3,
p.
332.
Moghaddam, Bita
and
Homayoun, Houman
2007.
Handbook of Contemporary Neuropharmacology.
Nilsson-Todd, Linda K.
Nordin, Conny
Jönsson, Erik G.
Skogh, Elisabeth
and
Erhardt, Sophie
2007.
Cerebrospinal fluid kynurenic acid in male patients with schizophrenia – correlation with monoamine metabolites.
Acta Neuropsychiatrica,
Vol. 19,
Issue. 1,
p.
45.
Rang, HP
Dale, MM
Ritter, JM
and
Flower, RJ
2007.
Rang &amp Dale's Pharmacology.
p.
545.
WEIDEN, PETER J.
2007.
EPS Profiles: The Atypical Antipsychotics.
Journal of Psychiatric Practice,
Vol. 13,
Issue. 1,
p.
13.
Sharif, Zafar
Miyamoto, Seiya
and
Lieberman, Jeffrey A.
2007.
Handbook of Contemporary Neuropharmacology.
GAO, Ming
LIU, Chang-liang
YANG, Shen
ZHEN, Xue-chu
and
JIN, Guo-zhang
2007.
l-Stepholidine increases the frequency of sEPSC via the activation of D1dopamine signaling pathway in rat prelimbic cortical neurons.
Acta Pharmacologica Sinica,
Vol. 28,
Issue. 5,
p.
627.
Guillin, Olivier
Demily, Caroline
and
Thibaut, Florence
2007.
Integrating the Neurobiology of Schizophrenia.
Vol. 78,
Issue. ,
p.
377.
Comments
No Comments have been published for this article.